The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2011Pathway Validation of a Biased Delta Opioid Receptor Ligand for PD Symptoms & Side Effects Relief
Objective/Rationale:
Endogenous activation of the Delta opioid receptor (DOR) serves as a compensatory mechanism to alleviate Parkinson’s disease (PD) symptoms. However, DOR-mediated convulsions have... -
MJFF Research Grant, 2011Assessing and Diagnosing Anxiety in Patients with Parkinson's Disease
Promising Outcomes of Original Grant:
A previous MJFF sponsored study showed that the available anxiety questionnaires are not suitable to assess anxiety in Parkinson’s disease (PD). The different... -
Rapid Response Innovation Awards, 2007Understanding the Molecular and Functional Changes of CB1/D2/A2A Receptor Complexes in the Hemi-parkinsonian Pre-clinical Model
Objective/Rationale:
Future therapies in Parkinson’s disease (PD) may derive from the existence of intramembrane heteromeric receptor complexes containing the dopamine D2 receptor. The ability of... -
Rapid Response Innovation Awards, 2013Evaluation of Targeted Plasticity Therapy as a Treatment for Motor Dysfunction in Parkinson’s Disease
Objective/Rationale:
Deterioration of motor function is a debilitating symptom of Parkinson’s disease (PD). We have recently developed a novel method that utilizes stimulation of the...
-
Research Grant, 2010Longitudinal Follow-Up of Clinical and Neuroimaging Signs and Biomarkers in Symptoms & Side Effects and aSymptoms & Side Effects LRRK2 Mutation Carriers in Comparison to Idiopathic PD and Controls
Objective/Rationale:
Parkinson’s disease (PD) is a common neurodegenerative disease that leads to progressive motor impairment as well as autonomic and cognitive disturbances. The cause of most of... -
Rapid Response Innovation Awards, 2014Disease-modifying Potential of Nortriptyline in Parkinson’s Disease
Objective/Rationale:
Aggregation of the protein alpha-synuclein is toxic to dopamine neurons. Therefore, a compound that reduces or clears this protein could be a viable therapeutic option...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.